Eli Lilly has agreed to acquire Wellesley-based biotech startup Calytrix Bio for up to $1.5 billion, expanding its footprint in rare blood cancer treatments. The transaction includes an undisclosed upfront cash payment and clinical milestone payouts. Calytrix Bio's lead program targets myeloproliferative neoplasms like myelofibrosis and essential thrombocythemia using a biparatopic antibody targeting CALR gene mutations. The deal represents Eli Lilly's 15th acquisition of 2026.
Terms of the Calytrix acquisition
- ▪Eli Lilly agreed to acquire Wellesley, Massachusetts-based biotech startup Calytrix Bio Inc. for up to $1.5 billion
- ▪The acquisition agreement between Eli Lilly and Calytrix Bio Inc. includes an undisclosed upfront cash payment and subsequent payouts tied to clinical trial and regulatory milestones
Statements from Calytrix Bio leadership
- ▪Calytrix Bio Inc. President and Chief Executive Officer Brad Prosek stated that Calytrix Bio Inc. looks forward to Eli Lilly advancing the treatment program through clinical trials
- ▪Calytrix Bio Inc. President and Chief Executive Officer Brad Prosek stated that Calytrix Bio Inc. was founded on the belief that patients with myeloproliferative neoplasms deserve therapies that do more than manage symptoms
Calytrix's lead blood cancer treatment
- ▪Calytrix Bio Inc. is developing an experimental biparatopic antibody designed to bind to two separate sites on mutated CALR cell-surface proteins while sparing healthy tissue
- ▪Calytrix Bio Inc.'s lead candidate is an early-stage antibody treatment for essential thrombocythemia and myelofibrosis
Characteristics and current treatments of myeloproliferative neoplasms
- ▪Myeloproliferative neoplasms are rare blood cancers originating in bone marrow that occur when the body overproduces red blood cells, leading to bone marrow scarring and blood clots
- ▪Existing therapies for myeloproliferative neoplasms include blood transfusions and JAK inhibitor drugs such as Incyte's Jakafi, which manage disease symptoms rather than targeting underlying mutations
Eli Lilly's 2026 acquisition strategy
- ▪Eli Lilly has pursued company acquisitions throughout 2026 to expand into oncology, hematology, and autoimmune diseases beyond its blockbuster diabetes and weight-loss franchise
- ▪Eli Lilly's acquisition of Calytrix Bio Inc. follows Eli Lilly's purchase of Ajax Therapeutics earlier in 2026 to expand into rare blood cancer treatments
- ▪The purchase of Calytrix Bio Inc. on November 16, 2026 marked Eli Lilly's 15th announced company acquisition of 2026, bringing its total 2026 acquisition spending to over $30 billion
Story comments
Loading comments…